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Scientific objectives
Monitoring changes in the levels of biomarkers PSA, %
freePSA, [-2] proPSA and calculation of PHI in the diag-
nostic algorithm of early prostate cancer.
Technological approaches
The Immunoanalytical Laboratory of University Hospital
in Pilsen examined sera of 76 patients from the Urology
department of the University Hospital with suspected
prostate cancer who have undergone TRUS biopsy. We
assessed the levels of PSA and, if the interval of PSA
was between 0-30 ng/mL, we also assessed the levels of
freePSA, [-2]proPSA and we calculated %freePSA and
Prostate Health Index (PHI). The monitored biomarkers
were measured using the chemiluminescent DxI 800
instrument (Beckman Coulter, USA). The peripheral
blood was drawn by VACUETTE ® (Greiner Bio-One,
Austria). All specimens were immediately aliquoted, fro-
zen and stored at -80°C. Samples were thaw only ones
just before the processing. SAS 9.2 software was used
for all statistical analysis.
Results interpretation
We found statistically significant increased levels of [-2]
proPSA and PHI in patients diagnosed with prostate
cancer by prostate biopsy vs. patients with benign pros-
tate hypertrophy ([-2]proPSA median 14 vs. 27 pg/mL,
PHI median 35 vs. 77). In the contrary, we did not find
any significant difference in tPSA and %freePSA (median
tPSA 7.1 vs. 7.7 ng/mL and %freePSA 16 vs.11.4%).
According to receiver operating characteristic (ROC)
curves is PHI the best parameter for distinguishing
benign and malignant prostate tumor (Figure 1).
Outlook and Expert recommendations
The assessment of [-2]proPSA and the calculation of PHI
appear to be of great benefit for a more accurate differen-
tial diagnosis of benign hyperplasia. PHI calculation leads
to a biopsy reduction and it is expected that the verifica-
tion in a larger file of patients will have significant impact
for the assessment of tumor aggressiveness.
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Figure 1 ROC curves of prostatic parameters
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